European Cancer Organisation
login

Session webcasts

 

Webcasts from 6 November

 

 

Agents targeting the mTOR-PI3K-Akt pathway
Presenter: J. Tabernero 

Keynote Lecture: November 6, 2012 14:00

Response-Adaptive Randomized Early Clinical Trials – can BATTLE and SPYs help in co- development of cancer drugs and diagnostics? Changing Landscape of Clinical Trial Design- Small Studies, Large Differences?
Presenter: E. Rubin

November 6, 2012 15:40

 

Incorporating Biomarkers Into Phase 2 Trials – 5 Multiple Options, Multiple Challenges Changing Landscape of Clinical Trial Design- Small Studies, Large Differences?
Presenter: L. Collette

November 6, 2012 16:05 

 

Enrichment Strategies for Patient Selection in 6 Early Oncology Trials – a Missed Opportunity, a Must or a way to Focus on the Wrong Target? Changing Landscape of Clinical Trial Design- Small Studies, Large Differences?
Presenter: J. Soria 

November 6, 2012 16:30

   

 

Webcasts from 7 November

 

Mechanisms of transformation by RAS oncogenes: searching for novel therapeutic approaches
Treating Kras Mutated Tumours
Presenter: J. Downward

November 07, 2012, 08:50

Is There an Optimal Biological Dose?
Challenges in Phase I
Presenter: L. Siu
 
November 07, 2012, 10:15
 

The Challenges of Drug Combination Studies
Challenges in Phase I
Presenter: J. de Bono

November 07, 2012 10:40

Pursuing Molecular Stratification in Phase I Trials
Challenges in Phase I
Presenter: R. Kurzrock

November 07, 2012 11:05

Patient Selection Markers for Anti-angiogenic Agents in Metastatic Renal Cell Carcinoma: Dream or Reality?
Proffered Paper Session
Presenter: J. Williams

November 07, 2012 15:00 

 

A First-in-human Phase I Study to Evaluate the Fully Human Monoclonal Antibody OMP-59R5 (anti-Notch2/3) Administered Intravenously to Patients with Advanced Solid Tumors
Proffered Paper Session
Presenter: D. Smith

November 07, 2012 15:30

A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors
Proffered Paper Session
Presenter: U. Lassen

November 07, 2012 15:45

Phenotypic Signaling Pathway Characterization in Complex Cell Populations for Treatment Selection and Response Assessment
Biomarkers for Antitumour Evaluation
Presenter: A. Cesano

November 07, 2012 16:30

Circulating Free DNA, Mutation Detection and Predictive Biomarker Potential
Biomarkers for Antitumour Evaluation
Presenter: K. Spindler

November 07, 2012 17:45

 

 

Webcasts from 8 November

 

 

Introducing Genomics into Clinical Trials
Next Generation Gene Sequencing: how to use?
Presenter: T. Zhang

November 08, 2012 08:00

 

Integrating Cancer Networks and the Value of Compute Spaces
Next Generation Gene Sequencing: how to use?
Presenter: S. Friend

November 08, 2012 09:10

 

Finding the Right Dose for the Population
Drug Dosing
Presenter: J. Verweij

November 08, 2012 10:15

 

Understanding and Managing INTER-Individual Pharmacokinetic Variability
Drug Dosing
Presenter: S. Baker

November 08, 2012 10:45

Understanding and managing intraindividual pharmacokinetic variability
Drug Dosing
Presenter: M. Ratain

November 08, 2012 11:15

 

Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors
Proffered Paper Session
Presenter: R. Bahleda

November 08, 2012 15:00

 

Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
Proffered Paper Session
Presenter: D. Petrylak

November 08, 2012 15:15

 

Targeting Tumour-Stroma Interaction for Prevention of Metastasis
Microenvironment
Presenter: N. Harbeck

November 08, 2012 16:55

 

Innate and adaptive immunity regulated within the tumor microenvironment
Microenvironment
Presenter: T. Gajewski

November 08, 2012 17:20

 

Webcasts from 9 November

 

Using Functional Genetics to Optimize the Treatment of Cancer
Drug Resistance in Targeted Agents

Presenter: R. Bernards

November 09, 2012 11:00

 

 

 

   
 

 

PRINT THIS PAGE Page last modified: